Red Blood Cell Alloimmunization in Multitransfused Pediatric Population in a Tertiary Care Hospital

Poornima, AP; Fazal, Shiffi; Shaiji, P S; Usha, K. C.; Kailas, Lalitha

doi:10.1007/s12098-018-2815-9

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PRISMA flow diagram is shown in Figure 1. The articles included in the review were published between 1999 and 2020 [8–51]. Studies in the multiply‐transfused group mostly comprised patients with thalassemia, sickle cell anaemia, oncology cases and renal failure.…”

Section: Resultsmentioning

confidence: 99%

Red blood cell alloimmunization among recipients of blood transfusion in India: A systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Background and Objectives There is a varied prevalence of red cell alloimmunization being reported from different parts of India. This study aimed to estimate the overall prevalence of alloimmunization in India by performing a systematic review of the literature and to establish the most suitable antigen‐matching strategy to reduce the red blood cell (RBC) alloimmunization rate among transfusion recipients. Materials and Methods A systematic search of all the original articles published in English on RBC alloimmunization among transfusion recipients from India in MEDLINE, SCOPUS, CINAHL and Google Scholar bibliographic databases was conducted. After screening the articles as per inclusion/exclusion criteria, data extraction was done independently by two sets of investigators. Meta‐analysis was performed by the binary random‐effects model using the restricted maximum likelihood method. Results A total of 44 studies on RBC alloimmunization, with a cumulative sample size of 309,986 patients, were grouped into hospital‐based and multiply‐transfused patients, which yielded a prevalence of 0.5 (95% confidence interval; 0.3–0.8) and 4.8 (95% confidence interval; 3.9–5.7) per 100 patients, respectively. As many as 1992 alloantibodies were identified among the 1846 alloimmunized patients. The most common antibody identified was anti‐E (127; 31.99%), followed by anti‐c (75; 18.89%) in multiply‐transfused patients. Conclusion The rate of alloimmunization was 0.5 per 100 patients tested for antibodies and 4.8 per 100 patients receiving transfusion. Considering E‐ and c‐antigen‐matched red cells along with ABO and RhD matching may significantly reduce the overall occurrence of alloimmunization among Indian population who are transfusion‐dependent.

show abstract

Section: Resultsmentioning

confidence: 99%

Red blood cell alloimmunization among recipients of blood transfusion in India: A systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

Prevalence and risk factors of alloimmunization in multi-transfused pediatric patients: A cross-sectional study from a sub-Himalayan tertiary care hospital in Uttarakhand India

Maini,

Kumar Rawat,

Kumar

et al. 2024

Transfusion Clinique et Biologique

View full text Add to dashboard Cite

Blood transfusion dynamics in Colombia: Unveiling patterns, reactions and survival rates in multitransfused patients

Bermúdez‐Forero,

García‐Otálora

2024

Vox Sanguinis

View full text Add to dashboard Cite

Background and ObjectivesThere is no consensus on a universally accepted threshold to categorize a patient as multitransfused. In 2019, Colombia established the definition of a multitransfused patient as someone who has received six or more blood components, irrespective of the time frame. This study aims to delineate the characteristics, adverse transfusion reactions (ATRs, definitions according to the International Society of Blood Transfusion [ISBT]) and survival rates in this population.Materials and MethodsWe performed an analysis from the data of all institutions engaged in blood component transfusions at the national level who notified events to the National Information System of Haemovigilance (SIHEVI‐INS), from January 2018 to December 2022. The selection criteria focused on individuals who not only exhibited ATRs but also received six or more blood components.ResultsAmong the 1,784,428 patients who received 6,637,271 blood components, an average of 3.7 components per patient was noted. Concurrently, 8378 ATRs were reported (12.6 ATRs/10,000 transfused components). Within this cohort, 691 patients met the criteria for multitransfusion. Predominantly women (51.8%), these individuals received between 6 and 14 blood components. Out of the 691 multitransfused individuals who experienced ATR, 541 had an allergic reaction. Conversely, out of the 6479 non‐multitransfused individuals who experienced ATR, 3835 had an allergic reaction (odds ratio: 2.49, 95% confidence interval: 2.06–3.0). Notably, 271 multitransfused individuals (39.2%) were documented as deceased, with 76% succumbing within 12 months of encountering their most recent ATR.ConclusionMultitransfused individuals in Colombia, being a high‐risk group, exhibit a heightened susceptibility to allergic reactions, surpassing the frequency observed in other transfusion populations. This underscores the necessity for tailored medical care specific to this group.

show abstract

Red Blood Cell Alloimmunization in Multitransfused Pediatric Population in a Tertiary Care Hospital

Cited by 4 publications

References 26 publications

Red blood cell alloimmunization among recipients of blood transfusion in India: A systematic review and meta‐analysis

Red blood cell alloimmunization among recipients of blood transfusion in India: A systematic review and meta‐analysis

Prevalence and risk factors of alloimmunization in multi-transfused pediatric patients: A cross-sectional study from a sub-Himalayan tertiary care hospital in Uttarakhand India

Blood transfusion dynamics in Colombia: Unveiling patterns, reactions and survival rates in multitransfused patients

Contact Info

Product

Resources

About